MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer’s disease and normal aging

Wang, Biao; Chalk, Jonathan B.; Rose, Stephen; Zubicaray, Greig I. de; Cowin, Gary; Galloway, Graham J.; Barnes, D.; Spooner, Donna; Doddrell, David M.; Semple, James

doi:10.1016/s0730-725x(02)00472-1

Cited by 50 publications

(39 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of multiple serial MRI and hence a longer assessment period in this study most likely reduced the within-subject variability (Schott, et al, 2006) and increased the power to differentiate these two disorders. The rate of atrophy observed in the AD subjects was however lower than has been previously reported in clinical cohorts of AD subjects , Schott, et al, 2005, Wang, et al, 2002. This difference could be due to a combination of factors.…”

Section: Discussioncontrasting

confidence: 66%

“…Increased rates of whole brain atrophy have been observed in subjects with both Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD) when compared to controls (Chan, et al, 2001, Ezekiel, et al, 2004, Jack, et al, 2004, Wang, et al, 2002, Whitwell, et al, 2007, and rates have been shown to be higher in subjects with FTLD compared to AD (Chan, et al, 2001, Whitwell, et al, 2007. Longitudinal studies using multiple serial MRI have also shown that the rates of atrophy in subjects with familial AD increase over the course of the disease as subjects progress from presymptomatic to moderate AD (Chan, et al, 2003, Ridha, et al, 2006.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease

et al. 2008

View full text Add to dashboard Cite

Rates of brain loss have been shown to accelerate over time in early Alzheimer's disease (AD); however the trajectory of change in frontotemporal lobar degeneration with ubiquitin immunoreactive-changes (FTLD-U) is unknown. This study compared the progression of atrophy over multiple MRI in subjects with autopsy confirmed AD and FTLD-U. Nine subjects with autopsy confirmed FTLD-U, and nine with autopsy confirmed AD, were identified that had three or more serial MRI. The boundary-shift integral was used to calculate change over time in whole brain and ventricular volume. A hierarchical regression model was used to estimate the slope of volume change in AD and FTLD-U over time and to estimate differences in the slopes across the subject groups. Whole brain volume loss did not deviate from a linear rate over time in both AD and FTLD-U subjects, although this may be due to limited sample size. The FTLD-U subjects had a faster rate (23ml/yr) than the AD subjects (10ml/yr). The rate of ventricular expansion accelerated over time. At the point when each subject had a Clinical Dementia Rating Sum-of-Boxes score of 6 the annual rate was 7ml/yr in FTLD-U and 5ml/yr in AD. These rates of change increased by an estimated 1.66ml/yr in FTLD-U, and 0.44ml/yr in AD, although these estimates were not significantly different between the two groups. The trajectory of brain and ventricular changes were similar in AD and FTLD-U suggesting that it is independent of pathology, although subjects with FTLD-U show a more rapidly progressive decline.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Some studies have reported higher atrophy rates for AD subjects although subjects were often more severely affected at the time of imaging. For example, O'Brien et al reported a brain atrophy rate of 2.0%/year (0.9%/year) in patients with a mean age of 75 and mean MMSE of 16 [9]; Fox et al reported a brain atrophy rate of 2.4%/year (1.1%/year) for a mean age of 65 and mean MMSE of 20 [30]; Archer et al reported a brain atrophy rate of 1.8%/year (1.4%/year) for a mean age of 66 and mean MMSE 21 [31]; Wang et al reported a brain atrophy rate of 2.4%/year (1.2%/year) for a mean age of 67 and mean MMSE 20 [32]; Sluimer et al reported a rate of 1.9%/year (0.9%/year) for a mean age of 67 years and mean MMSE 22 [12]. The mean MMSE in ADNI is higher than the studies reported above, as ADNI enrolled at an early disease stage.…”

Section: Discussionmentioning

confidence: 99%

“…Reported rates of ventricular enlargement in AD are varied, ranging from 4 to 10 ml/year. Silbert et al reported a ventricular change of 5.5 ml/year (3.2 ml/year) for a mean age of 82 and final MMSE of 12 [36]; Schott et al reported a ventricular change of 4.3 ml/year (2.4 ml/year) for a mean age 70 and MMSE of 20 [37]; Kaye et al reported a ventricular change of 9.9 ml/year (5.8 ml/year) in mild AD for a mean age of 76 and mean MMSE 22 [38]; Wang et al reported a ventricular change of 8.2 ml/year (no SD given) for a mean age of 67 and mean MMSE of 19.6 [32]. Silbert et al included older subjects than our study and with a much lower MMSE, yet reported ventricular rates that are comparable [36].…”

Section: Discussionmentioning

confidence: 99%

Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations

et al. 2009

View full text Add to dashboard Cite

Objective: To assess the relationship between MRI-derived changes in whole-brain and ventricular volume with change in cognitive scores in Alzheimer's disease (AD), mild cognitive impairment (MCI) and control subjects. Material and methods: In total 131 control, 231 MCI and 99 AD subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort with T1-weighted volumetric MRIs from baseline and 12-month follow-up were used to derive volume changes. Mini mental state examination (MMSE), Alzheimer's disease assessment scale (ADAS)-cog and trails test changes were calculated over the same period. Results: Brain atrophy rates and ventricular enlargement differed between subject groups (p<0.0005) and in MCI and AD were associated with MMSE changes. Both measures were additionally associated with ADAS-cog and trails-B in MCI patients, and ventricular expansion was associated with ADAS-cog in AD patients. Brain atrophy (p<0.0005) and ventricular expansion rates (p=0.001) were higher in MCI subjects who progressed to AD within 12 months of follow-up compared with MCI subjects who remained stable. MCI subjects who progressed to AD within 12 months had similar atrophy rates to AD subjects. Conclusion: Whole-brain atrophy rates and ventricular enlargement differed between patient groups and healthy controls, and tracked disease progression and psychological decline, demonstrating their relevance as biomarkers.

show abstract

“…Combining temporal lobe atrophy rate with ventricular enlargement rate, the discriminant function completely separated normal elderly and people with AD. 91 Table 1 summarizes the literature on serial MR-based volume measurements in AD.…”

Section: Both Antemortem and Postmortem Mr Studies Indicate That Mr-bmentioning

confidence: 99%

Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease

Kantarci

Jack

2004

Neurotherapeutics

View full text Add to dashboard Cite

Summary: Recent advances in understanding the molecular biology of Alzheimer's disease (AD) offer the promise of useful therapeutic intervention in the foreseeable future. Hence, improved methods for early diagnosis and noninvasive surrogates of disease severity in AD have become more imperative. Various quantitative magnetic resonance (MR) techniques that measure the anatomic, biochemical, microstructural, functional, and blood-flow changes are being evaluated as possible surrogate measures of disease progression. Cross-sectional and longitudinal studies indicate that MR-based volume measurements are potential surrogates of disease progression in AD, starting from the preclinical stages. The validity of MR-based volumetry as a surrogate marker for therapeutic efficacy in AD remains to be tested in a positive disease-modifying drug trial. Recent development of amyloid imaging tracers for positron emission tomography has been a major breakthrough in the field of imaging markers for AD. Efforts to image plaques are also underway in MR imaging. As with indirect MR measures, these approaches of directly imaging the pathological substrate will need to undergo a validation process with longitudinal studies to prove their usefulness as surrogate markers in AD.

show abstract

MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer’s disease and normal aging

Cited by 50 publications

References 28 publications

Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease

Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease

Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations

Quantitative magnetic resonance techniques as surrogate markers of Alzheimer’s disease

Contact Info

Product

Resources

About